Keegan et al. 122 observed that decreased levels of IL-6 were associated with better FPS in patients with NSCLC who received immunotherapy than those with high or normal levels of IL-6 (median PFS: 11 vs 4 months). This evidence concerns the gene IL6 and non-small cell lung carcinoma.